Filana Therapeutics FLNA

Filana Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Austin, Texas that focuses on developing transformative medicines for central nervous system disorders linked to dysregulation or overexpression of the filamin A protein. The company’s lead product candidate, simufilam, is a proprietary small‑molecule oral therapy designed to modulate filamin A activity and is currently being investigated for the treatment of Tuberous Sclerosis Complex‑related epilepsy after the discontinuation of its Alzheimer’s disease program in mid-2025. Prior to that discontinuation, simufilam had been evaluated in two Phase 3 Alzheimer’s studies (RETHINK‑ALZ and REFOCUS‑ALZ) involving a total of approximately 1,900 patients and in a 24‑month Phase 2 safety study enrolling over 200 participants. The drug’s mechanism is based on preclinical findings that simufilam reduces seizure activity and limits neuronal abnormalities in mouse models of TSC‑related epilepsy and focal cortical dysplasia type II, effects comparable to genetic knockdown of filamin A. In December 2025 the company submitted an Investigational New Drug application for simufilam in TSC‑related epilepsy, which the FDA placed on a full clinical hold pending additional preclinical data and protocol revisions, and the company is working to address the hold’s requirements.

Filana Therapeutics does not generate revenue from product sales because it has no approved therapeutics; its income is derived mainly from research grants and collaborative agreements. The company has received funding from the National Institutes of Health to support clinical safety studies of simufilam, although the specific award amounts are not disclosed in the filing. In February 2025 it entered into a license agreement with Yale University that obligates it to pay milestone payments of up to $4.5 million upon achievement of clinical, regulatory and commercial milestones and tiered royalties ranging from a low- to mid-single-digit percentage on any future net sales of licensed products. Until a product obtains regulatory approval, the company’s cash inflows are limited to such grant income and any potential milestone receipts, while its expenditures are reflected in research and development costs of $26.6 million for the year ended December 31, 2025, $69.6 million for 2024 and $89.4 million for 2023. The firm employs 17 full-time staff members and three employees who devote a portion of their professional time to the company as of the end of 2025, and it relies entirely on third‑party vendors for manufacturing, with simufilam supplied by Evonik Industries AG under a drug supply agreement.

Within the biotechnology sector, Filana Therapeutics occupies an early‑stage niche focused on novel central nervous system therapies, competing against larger pharmaceutical companies that market established treatments for TSC‑related epilepsy such as Afinitor Disperz (everolimus) and Epidiolex (cannabidiol), as well as numerous biotech firms pursuing similar molecular targets. The company’s competitive advantages stem from its exclusive worldwide rights to simufilam through a robust patent portfolio—including nine issued U. S. patents with expiration dates ranging from 2029 to 2040—and the Yale license, which together cover composition of matter and methods of use in the United States, Europe, Australia, Israel, Canada and Japan. In addition to owned patents, Filana Therapeutics holds pending patent applications for diagnostic assets related to simufilam in the United States, Europe, Japan, China, Canada and Australia. The exclusive license grants the right to sublicense the licensed intellectual property and includes customary diligence obligations, milestone payments and royalties. Simufilam represents a potential first‑in‑class filamin A‑modulating agent, a mechanism supported by preclinical data showing seizure reduction in mouse models of TSC‑related epilepsy and focal cortical dysplasia type II, and the company continues to explore other indications where its preclinical experiments suggest a benefit.

The company’s customer base consists primarily of patients with central nervous system disorders, especially those suffering from TSC‑related epilepsy who are enrolled in its clinical trials. Filana Therapeutics collaborates with academic institutions such as Yale School of Medicine, patient advocacy groups including the Tuberous Sclerosis Alliance, and contract research organizations like PsychoGenics, which conducted the preclinical Tsc1‑CKO mouse study that evaluated simufilam’s effect on seizure progression. Manufacturing of simufilam is outsourced to Evonik Industries AG, a contract development and manufacturing organization that supplies clinical‑grade quantities of the drug substance for trial use. The company has also worked with clinical sites across the United States; its Phase 2 Alzheimer’s safety study enrolled participants from 16 U. S. clinical sites, and its planned TSC‑related epilepsy trial would similarly rely on a network of investigators and trial centers. These partners, trial sites and suppliers constitute the primary recipients of the company’s research, development and operational activities.